fda pulling semaglutide US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list Navigating changes in access to

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UKBM

We recommend discarding the vial and starting over to ensure the integrity of your research

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity

The variance in first-month outcomes reflects differences in adherence, diet quality, physical activity level, and genetic predisposition to GLP-1 receptor sensitivity

[PMID: 39761583] PubMed record related to this compound for laboratory literature review